World Implantable Loop Recorders Market 2020-2026 - Regional Insights Into Atrial Fibrillation, Cardiac Arrhythmia, and Cardiac Syncope Applications by End-user
August 26, 2020 08:08 ET
|
Research and Markets
Dublin, Aug. 26, 2020 (GLOBE NEWSWIRE) -- The "Global Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals, Cardiac...
MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure
June 22, 2020 08:00 ET
|
MyoKardia, Inc.
Danicamtiv was Well Tolerated; Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction New...
Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions
May 07, 2020 08:30 ET
|
ARCA biopharma, Inc.
New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence ° 26% reduction in total time spent...
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
May 06, 2020 16:30 ET
|
ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as a potential treatment...
Conformal Medical Announces First Left Atrial Appendage Closures Performed Under Conscious Sedation with its CLAAS Technology at AF Symposium 2020
January 22, 2020 08:50 ET
|
Conformal Medical, Inc.
NASHUA, N.H., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Conformal Medical, Inc. announced today the presentation of the first left atrial appendage closure (LAAC) cases with its unique CLAAS® Technology in...
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
September 12, 2019 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 12, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
September 11, 2019 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update
August 01, 2019 16:30 ET
|
ARCA biopharma, Inc.
FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction (HFpEF)PRECISION-AF...
Atrial Fibrillation Market To Reach USD 14.68 Billion By 2026| Reports And Data
May 27, 2019 13:07 ET
|
Reports And Data
Increase in number of heart diseases coupled with technological advancements globally, are the major factors influencing market growth. Market Size – USD 5.08 billion in 2018, Market Growth - CAGR of...
ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure
May 13, 2019 09:00 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 13, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...